多价疫苗-KLH偶联物(NSC 748933 IND# 14384)联合OPT-821对比OPT-821在第二或第三次完全缓解的上皮性卵巢癌、输卵管癌或腹膜癌患者中的II期随机双盲试验:NRG Oncology/GOG研究
本II期随机双盲试验将171例化疗后第二或第三次临床完全缓解的上皮性卵巢癌、输卵管癌或腹膜癌患者按1:1随机分配接受OPT-821联合疫苗-KLH偶联物或单用OPT-821皮下注射。疫苗联合OPT-821组与单用OPT-821组相比无进展生存期风险比为0.98(95%CI:0.71-1.36),中位随访60个月时中位总生存期分别为47个月和46个月。联合方案免疫原性 modest,未延长无进展生存期或总生存期。
要点
- 疫苗联合OPT-821组与单用OPT-821组的无进展生存期风险比为0.98(95%CI:0.71-1.36)。
- 中位随访60个月时,两组中位总生存期分别为47个月和46个月。
- 多数患者为浆液性组织学(85%)、诊断时III期(77%)、既往接受2种方案(68%)。
核心结论
- 疫苗联合OPT-821与单用OPT-821相比免疫原性 modest,未延长无进展生存期或总生存期。
- 多次缓解患者是探索创新巩固和维持治疗方法的可行、定义明确的人群。
研究设计与样本
- II期随机双盲试验,2010年至2013年纳入171例患者,随机1:1分配,170例接受治疗。
- 患者为化疗后第二或第三次临床完全缓解的上皮性卵巢癌、输卵管癌或腹膜癌患者。
- 皮下注射OPT-821联合或不联合疫苗-KLH偶联物,第1、2、3、7、11周给药,之后每12周给药,共11次。
- 不允许剂量延迟或减量,因预设剂量限制性毒性移除患者。
主要发现
- 多数患者为浆液性组织学(85%)、诊断时III期(77%)、既往接受2种方案(68%)。
- 32%接受超过6个治疗周期(中位数6,每组,p=0.33)。
- 77%因疾病进展中止,4%因毒性中止,1例因骨髓增生异常综合征(MDS)中止。
- 最大毒性包括4级MDS和抑郁/人格改变(各1例,不太可能相关),以及3级胃肠道疾病和其他(n=21,4例相关)。
- 较轻不良事件为注射部位反应(82%)和发热(11%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Early-phase data have demonstrated induction of antibody responses to a polyvalent vaccine conjugate (Globo-H, GM2, MUC1-TN, TF) with adjuvant OPT-821. We sought to determine if this combination decreases the hazard of progression or death compared to OPT-821 alone in patients with ovarian cancer in second/third clinical complete remission following chemotherapy. Secondary and translational objectives were overall survival (OS), safety, and immunogenicity. METHODS: From 2010-2013, patients were randomized (1:1) to receive OPT-821±vaccine-KLH conjugate subcutaneously at weeks 1, 2, 3, 7, 11, and then every 12 weeks (total 11). Dose delay or reduction was not permitted. Patients were removed for pre-defined dose-limiting toxicity. RESULTS: Of 171 patients randomized, 170 were treated. Most had disease of serous histology (85%), stage 3 disease at diagnosis (77%), and had received 2 prior regimens (68%). 32% received >6 treatment cycles [median 6, each arm (p = 0.33)]. 77% discontinued due to progression, 4% due to toxicity, and 1 due to myeloid dysplastic syndrome (MDS). Maximum toxicities included grade 4 MDS and depression/personality change (1 each, unlikely related), as well as grade 3 gastrointestinal disorders and others (n = 21, 4 related). Lesser adverse events were injection site reactions (82%) and fever (11%). Estimated HR for progression-free survival (PFS) of the vaccine + OPT-821 to OPT-821 arm was 0.98 (95% CI: 0.71-1.36). At a median follow-up of 60 months, median OS was 47 and 46 months, respectively. CONCLUSIONS: Vaccine + OPT-821 compared to OPT-821 alone was modestly immunogenic and did not prolong PFS or OS. Multi-remission patients are a viable, well-defined population for exploring innovative consolidation and maintenance approaches. TRIAL REGISTRATION: NCT00857545.
引用
- O'Cearbhaill RE, Deng W, Chen LM, et al. A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study. Gynecol Oncol. 2019. PMID: 31653510. doi:10.1016/j.ygyno.2019.09.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。